“Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy” (2016) Farmeconomia. Health economics and therapeutic pathways, 17(3). doi:10.7175/fe.v17i3.1264.